Why Citigroup Removed Gilead Sciences From Its ‘Most Preferred’ List

Last night, Citigroup’s Yaron Werber and team removed Gilead Sciences (GILD) from its tactical “Most Preferred” list–leaving just Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) among large caps–and added Alexion Pharmaceuticals (ALXN) to their “Least Preferred” list. Gilead Sciences Now, Werber’s list shouldn’t be confused with his ‘Buy’ and ‘Sell’ recommendations. Instead, its his way of “call[ing] out [...]